Crescent Biopharma, Inc. (CBIO)
12.65
+1.18
(+10.29%)
USD |
NASDAQ |
Feb 24, 16:00
12.66
+0.01
(+0.08%)
After-Hours: 20:00
Crescent Biopharma Research and Development Expense (Quarterly) : 20.35M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| XOMA Royalty Corp. | 0.069M |
| Viridian Therapeutics, Inc. | 86.15M |
| DiaMedica Therapeutics, Inc. | 6.437M |
| Denali Therapeutics, Inc. | 101.95M |
| Praxis Precision Medicines, Inc. | 77.51M |